All In Biotech

Drug Trial Radar · NCT01339689

Ganaxolone in Posttraumatic Stress Disorder (PTSD)

A Proof-of-Concept, Double-blind, Randomized, Placebo-controlled Study of Ganaxolone in Posttraumatic Stress Disorder

Last checked: Nov 19, 2026Latest source record: Dec 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 112 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

112

Actual

Start

Apr 2011

Primary completion

Jan 2014

Study completion Mar 2014

Sponsor

Lead sponsor
Marinus PharmaceuticalsIndustry
Sponsor type
Industry
Collaborators
INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium; U.S. Army Medical Research and Development Command
First posted
Apr 21, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 2 proof-of-concept study is a double-blind, randomized, placebo-controlled, 15-week investigation of ganaxolone versus placebo for the treatment of Posttraumatic Stress Disorder (PTSD). Up to 120 participants will be enrolled and randomized to receive either ganaxolone or placebo for 6 weeks. After 6 weeks of randomized treatment all participants will continue for 6 weeks on ganaxolone. The aim of the study is to assess the efficacy of ganaxolone compared to placebo for the treatment of PTSD symptoms after 6 weeks of treatment using the Clinician-Administered PTSD Rating Scale (CAPS). The second aim of the study is to evaluate the safety and tolerability of ganaxolone in the PTSD population.

Conditions

  • PTSD

Interventions

  • GanaxoloneDrug

    200-600 mg bid, capsules, up to 12 weeks

  • PlaceboDrug

    capsules, bid, up to 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Clinician-Administered Posttrautamtic Stress Disorder (PTSD) Scale (CAPS) to Week 6Time frame: Baseline (Week 0) and at Week 2, Week 4 and Week 6

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • VA San Diego Healthcare System/ University of California, San Diego

    San Diego, California

  • Washington DC VA Medical Center/ Uniformed Services University of the Health Services

    Washington D.C., District of Columbia

  • VA Boston Healthcare Services/ Spaulding Rehabilitation Hospital

    Boston, Massachusetts

  • Manchester VA Medical Center/ Dartmouth College

    Manchester, New Hampshire

  • Durham VA Medical Center /Duke University Medical Center

    Durham, North Carolina

  • Cincinnati VA Medical Center/ University of Cincinnati

    Cincinnati, Ohio

  • Charleston VA Medica Center/ Medical University of South Carolina

    Charleston, South Carolina

  • White River Junction VA Medical Center/ Dartmouth College

    White River Junction, Vermont

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.